Mitochondria-mediated tumor drug resistance: From mechanism insights to therapeutic strategies
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026-09 · 1881 (4) · 189624
DOI: 10.1016/j.bbcan.2026.189624 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026-09. Verfasst von Peixian Pi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai University of Traditional Chinese Medicine, Shanghai 201203, PR China; Shanghai Key Laboratory of Molecular Imaging & Digital and Intelligen…. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Mitochondria, Neoplasms, Antineoplastic Agents. Die Arbeit nennt 121 Literaturangaben. Gefördert von: Shanghai Key Laboratory of Molecular Imaging, National Natural Science Foundation of China, Shanghai Municipal Natural Science Foundation.
Abstract (Originalsprache)
Drug resistance remains a major barrier to durable responses to chemotherapy, targeted therapy, radiotherapy, and immunotherapy. Mitochondria, once viewed mainly as bioenergetic organelles, are now recognized as adaptive signaling hubs that shape tumor survival under therapeutic pressure. Here, we review how mitochondrial dynamics, metabolic plasticity, redox remodeling, programmed cell death regulation, epithelial-mesenchymal transition, and intercellular mitochondrial transfer collectively drive tumor drug resistance. We highlight that resistant cancer cells exploit mitochondrial flexibility to switch between glycolysis and oxidative phosphorylation, reinforce antioxidant defenses, suppress apoptosis, ferroptosis, and cuproptosis, and remodel the tumor microenvironment through metabolic and immune crosstalk. We further discuss emerging therapeutic strategies targeting mitochondrial vulnerabilities, including OXPHOS inhibition, fusion-fission modulation, redox intervention, BH3 mimetics, ferroptosis/cuproptosis induction, and mitochondria-directed delivery systems. Finally, we propose a mechanism-guided translational framework to advance mitochondria-targeted therapies toward biomarker-driven precision oncology. This integrated perspective may help move mitochondria-targeted therapy from a broad preclinical concept toward biomarker-guided precision strategies for overcoming tumor drug resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai University of Traditional Chinese Medicine, Shanghai 201203, PR China; Shanghai Key Laboratory of Molecular Imaging & Digital and Intelligent Empowerment Biomedical Innovation Center, Pudong Gongli Hospital, Sh…
- Shanghai Key Laboratory of Molecular Imaging & Digital and Intelligent Empowerment Biomedical Innovation Center, Pudong Gongli Hospital, Shanghai University of Medicine and Health Sciences, Shanghai 201318, PR China; Sc…
Förderung
- Shanghai Key Laboratory of Molecular Imaging
- National Natural Science Foundation of China
- Shanghai Municipal Natural Science Foundation
Zitieren
APA
Pi, P., Yang, L., Xie, W., Zhao, J., & Liang, B. (2026). Mitochondria-mediated tumor drug resistance: From mechanism insights to therapeutic strategies. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1881(4), 189624. https://doi.org/10.1016/j.bbcan.2026.189624
Vancouver
Pi P, Yang L, Xie W, Zhao J, Liang B. Mitochondria-mediated tumor drug resistance: From mechanism insights to therapeutic strategies. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026;1881(4):189624. doi:10.1016/j.bbcan.2026.189624
BibTeX
@article{Pi2026,
author = {Pi, Peixian and Yang, Lu and Xie, Wei and Zhao, Jian and Liang, Beibei},
title = {Mitochondria-mediated tumor drug resistance: From mechanism insights to therapeutic strategies},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2026},
volume = {1881},
number = {4},
pages = {189624},
doi = {10.1016/j.bbcan.2026.189624}
}
EUVIMED